Aurdan Capital Management LLC Has $2.04 Million Stake in Medtronic PLC $MDT

Aurdan Capital Management LLC lessened its holdings in shares of Medtronic PLC (NYSE:MDT) by 4.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,390 shares of the medical technology company’s stock after selling 1,130 shares during the period. Aurdan Capital Management LLC’s holdings in Medtronic were worth $2,039,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of MDT. Brighton Jones LLC lifted its holdings in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares in the last quarter. Private Trust Co. NA lifted its holdings in shares of Medtronic by 10.2% during the 1st quarter. Private Trust Co. NA now owns 9,349 shares of the medical technology company’s stock valued at $840,000 after purchasing an additional 863 shares in the last quarter. Checchi Capital Advisers LLC lifted its holdings in shares of Medtronic by 8.8% during the 1st quarter. Checchi Capital Advisers LLC now owns 6,731 shares of the medical technology company’s stock valued at $605,000 after purchasing an additional 547 shares in the last quarter. Aviance Capital Partners LLC lifted its holdings in shares of Medtronic by 3.4% during the 1st quarter. Aviance Capital Partners LLC now owns 4,524 shares of the medical technology company’s stock valued at $407,000 after purchasing an additional 148 shares in the last quarter. Finally, OneDigital Investment Advisors LLC lifted its holdings in shares of Medtronic by 495.4% during the 1st quarter. OneDigital Investment Advisors LLC now owns 82,413 shares of the medical technology company’s stock valued at $7,406,000 after purchasing an additional 68,571 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling

In other news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director William R. Jellison acquired 2,500 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was acquired at an average cost of $92.37 per share, with a total value of $230,925.00. Following the completion of the transaction, the director owned 5,000 shares of the company’s stock, valued at approximately $461,850. The trade was a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

MDT has been the subject of several recent research reports. Truist Financial upped their price objective on Medtronic from $96.00 to $103.00 and gave the stock a “hold” rating in a research report on Wednesday, October 15th. Daiwa Capital Markets upped their price objective on Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Morgan Stanley reaffirmed an “overweight” rating and set a $107.00 price objective (up from $98.00) on shares of Medtronic in a research report on Tuesday, July 15th. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Citigroup upped their price objective on Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.82.

Medtronic Trading Down 0.2%

Shares of Medtronic stock opened at $90.82 on Friday. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $99.37. The stock has a market cap of $116.49 billion, a P/E ratio of 25.02, a P/E/G ratio of 2.42 and a beta of 0.78. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The business’s 50 day moving average is $94.35 and its 200-day moving average is $89.72.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company had revenue of $8.58 billion for the quarter, compared to analysts’ expectations of $8.37 billion. During the same quarter in the prior year, the business posted $1.23 EPS. The business’s revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s dividend payout ratio is currently 78.24%.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.